PMHNP Exam Flashcards
The CRAFFT
It consists of a series of 6 questions developed to screen adolescents for high-risk alcohol and other drug use disorders simultaneously.
* Have you ever ridden in a CAR driven by someone (including yourself) who was high or had been using alcohol or drugs?
* Do you ever use alcohol or drugs to RELAX, feel better about yourself, or fit in?
* Do you ever use alcohol or drugs while you are by yourself ALONE?
* Do you FORGET things you did while using alcohol or drugs?
* Do your FAMILY or FRIENDS ever tell you that you should cut down on your drinking or drug use?
* Have you ever gotten into TROUBLE while you were using alcohol or drugs?
Administration: The CRAFFT is a self-administered screening but it can be read to the adolescent if necessary.
Scoring and interpretation: Score (1) point for each “YES” answer. A score of (2) or more indicates the need for further assessment.
CAGE-AID
- Have you ever felt you should cut down on your drinking or drug use?
- Have people annoyed you by criticizing your drinking or drug use?
- Have you ever felt bad or guilty about your drinking or drug use?
- Have you ever had a drink or used drugs first thing in the morning (eye opener) to steady your nerves or to get rid of a hangover?
“0” for no and “1” for yes. A score of 1 or above accurately detects 91% of alcohol users and 92% of drug users. A score of 2 or greater is considered clinically significant.
Screening Brief Intervention Referral to Treatment (SBIRT):
Screen for substance abuse disorders
- The practice delivery for brief intervention is guided by the acronym FRAMES:
o Feedback-tell them about the risks of their current level of alcohol use.
o Responsibility – reinforce any decision to change (or not) lies with the service user.
o Advice – based on facts about their drinking, offer simple and direct advice to the service user re: impact on them and offer your advice to change.
o Menu – provide them with a menu of options for behavior change.
o Empathetic interviewing – consider their perspective/ be non-judgmental.
o Self – efficacy – encourage the person to believe they can change.
Signs and Symptoms of alcohol withdrawal
- Nausea and vomiting
- Tremors
- Paroxysmal sweats
- Tactile disturbances
- Auditory disturbances
- Visual disturbances
- Headaches
- Anxiety
- Agitation
- Altered sensorium
Delirium
- **Acute onset
- **Altered level of consciousness
- **Inattention
- **Confusion
- Changes in cognition
- Poor prognosis: 1-year mortality rate of clients with delirium is up to 40%
Pharmacological Management of Delirium
Symptomatic treatment for agitation and psychotic symptoms
* Antipsychotic agents
* **Haloperidol (Haldol): Haloperidol is the preferred treatment for agitated delirious patients (as described by the guidelines of the American Psychiatric Association).
* Atypical antipsychotic agents
* Anxiolytic agents for insomnia
Nonpharmacological Management of Delirium
- Monitor for safety needs.
- Pay attention to basic needs.
- It is helpful to have in the client’s room familiar people; familiar pictures or decorations; a clock or calendar; and regular orientation to person, place, or time.
Dementia
Dementia is a group of disorders characterized by graual development of multiple cognitive deficits:
* Impaired executive functioning
* Impaired global intellect
* Impaired problem-solving
* Impaired organizational skills
* Altered memory
Dementia of Alzheimer’s type (DAT)
- Most common type
- Classified as a cortical dementia.
- ***Gradual onset and progressive decline without focal neurological deficits
Dementia due to HIV disease
- Classified as a subcortical dementia.
- Early signs of HIV dementia: Cognitive decline, motor abnormalities *(lack of coordination, tremors, dystonia, ataxia), and behavioral abnormalities
Clinical signs of late-stage HIV-related dementia
- Global cognitive impairment
- Mutism
- Seizures
- Hallucinations
- Delusions
- Apathy
- Mania
Lewy body disease
- Presents with **recurrent visual hallucinations. **
- Parkinson feature (bradykinesia, tremor)
- Adversely react to antipsychotics especially typical antipsychotics.
Vascular dementia (VD)
- Second most common type.
- Primarily caused by cardiovascular disease and characterized by step-type declines.
- Most common with men with preexisting high blood pressure and cardiovascular risk factors.
- **Hallmarks: carotid bruits, fundoscopic abnormalities, and enlarged cardiac chambers
Pick’s disease
- Also known as frontotemporal dementia/frontal lob dementia.
- More common in men
- **Personality, behavioral, and language changes (slurred) in early stage.
- Cognitive changes can occur in later stages.
Huntington’s disease
Subcortical type of dementia
* Characterized mostly by motor abnormalities
* Psychomotor slowing and difficulty with complex tasks.
* High incidence of depression and psychosis.
Etiology of dementia
- Diffuse cerebral atrophy and enlarged ventricles in dementia of Alzheimer’s type (DAT)
- ***Decreased acetylcholine and norepinephrine in DAT
- Genetic loading
o Family history of dementia in first-order relative
Psychosis and agitation in Dementia
- ***Try nonpharmacological therapies first.
- ***Atypical antipsychotics should be used as first-line agents in patients with psychotic symptoms of dementia.
-
**Use lowest effective dose and attempt to wean periodically.
o **Benzodiazepines should be avoided, if possible, in most patients with dementia, as they are particularly vulnerable to their adverse effects such as sedation, falls, and delirium.
Primary prevention:
- Aimed at decreasing the incidence (number of new cases) of mental disorders.
- Example: Stress management classes for graduate students, smoking prevention classes.
Secondary prevention:
- Aimed at decreasing the prevalence (number of existing cases) of mental disorders.
- Screening
- Example: telephone hotlines, crisis intervention, disaster responses
Tertiary prevention:
- Aimed at decreasing the disability and severity of a mental disorder
- Rehabilitative services
- Avoidance or postponement of complications
o Example: Day treatment programs; case management for physical, housing, or vocational needs; social skills training.
The guiding principles of Motivational Interviewing
Ask Open-ended questions
* The patient does most of the talking.
* Gives the provider the opportunity to learn more about what the patient cares about (e.g., their values and goals).
* Example: I understand you have some concerns about your drinking. Can you tell me about them? Verses Are you concerned about your drinking?
Make Affirmations
* Can take the form of compliments or statements of appreciation and understanding.
* Helps build rapport, validates, and supports the patient during the process of change.
* Most effective when the patient’s strengths and efforts for change are noticed and affirmed.
Example:
* I appreciate that it took a lot of courage for you to discuss your drinking with me today.
* You appear to have a lot of resourcefulness to have coped with these difficulties for the past few years.
Use Summarizing
* Ensure mutual understanding of the discussion so far.
* Links discussions and ‘checks in’ with the patient.
* Point out discrepancies between the person’s current situation and future goals.
* Demonstrates listening and understanding of the patient’s perspective.
Example:
If it is okay with you, just let me check that I understand everything that we’ve been discussing so far. You have been worrying about how much you’ve been drinking in recent months because you recognize that you have experienced some health issues associated with your alcohol intake, and you’ve had some feedback from your partner that she isn’t happy with how much you’re drinking. But the few times you’ve tried to stop drinking have not been easy, and you are worried that you can’t stop. How am I doing?
The guiding principles of Motivational Interviewing
Express Empathy Listen rather than talk; communicate respect for and acceptance of client
Avoid Argumentation Avoid confronting denial; encourage the client to make progress toward change
Roll with Resistance Divert or direct the client toward positive change; listen more carefully
Develop Discrepancy Promote the client’s awareness of consequences of continued use; clarify how present behavior is in conflict with important goals
Support Self-Efficacy Elicit and support hope; encourage the client’s capacity to reach their goals
Transtheoretical model of change-Precontemplation
a. ***The person is not aware that there is a problem with their behavior. **
b. The person has not intention to change.
Action step for Precontemplation stage
***Provide information and feedback to raise the person’s awareness of the problem and the possibility of change. Do not give prescriptive advice.
Transtheoretical model of change-Contemplation Stage
The person is thinking about changing; is aware that there is a problem but not committed to changing.
Action Step for Contemplation Stage
***Help the person see the benefits of changing and the consequences of not changing.
Transtheoretical model of change-Preparation Stage
The person has made the decision to change; is ready for action.
Action Step for Preparation Stage
***Help the person find a change strategy that is realistic, acceptable, accessible, appropriate, and effective.
Transtheoretical model of change-Action Stage
The person is engaging in specific, overt actions to change.
Action Step for Action Stage
***Support and be an advocate for the person. Help accomplish the steps for change.
Transtheoretical model of change-Maintenance Stage
The person is engaging in behaviors to prevent relapse.
Action Plan for Maintenance Stage
***Help the person identify the possibility of relapse and identify and use strategies to prevent relapse.
- Transtheoretical model of change-Relapse
- “When was your last relapse?”
- What led to the relapse and what are your plans for getting past it and avoiding another relapse?”
- “What keeps you from having another relapse?”
Action Plan for Relapse
Help the person holistically look at the situation.
Kindling
The tendency of some regions of the brain to react to repeated low-level bioelectrical stimulation by progressively boosting synaptic discharges, thereby lowering seizure thresholds.
Addiction
Compulsive substance use despite harmful consequence.
Potency
The amount of drug required to produce an effect of given intensity.
Give ______ for a high potency medication like haldol
Low Dose
Give ____ for low potency medication, like chlopromazine
High Dose
Etiology of ADHD
**Abnormalities of fronto-subcortical pathways (Refer PB 336)
* Frontal cortex
* Basal ganglia (motor control, motor learning, executive functions and behaviors, and emotions).
Abnormalities of reticular activating system (ability to focus, fight-flight response, regulating arousal and sleep-wake transitions). **
Structural abnormalities producing neurotransmitter abnormalities
* Dopamine dysfunction
* Norepinephrine dysfunction
* Serotoinin
Mnemonic: DNS
Pharmacological Management ADHD-Stimulants
(Adderall and methylphenidate)
* Assess cardiac history before placing patient on stimulants (amphetamines for example can cause elevated heart rate and blood pressure, and increase risk of heart attack, and stroke).
* Amphetamines are approved in children ages 3 years and older.
* Methylphenidate are approved in children ages 6 years and older.
Pharmacological Management of ADHD-Non-Stimulants
- Alpha agonist or alpha 2 adrenergic receptor agonist: Guanfacine and Clonidine is FDA approved in ages 6-17 years with ADHD.
- Strattera (Atomoxetine) (selective norepinephrine reuptake inhibitor) is approved for children aged 6 and older with ADHD.
Signs of stimulants abuse
- ***Insomnia
- ***Tremors
- ***Increase blood pressure and heart rate
- ***Heart palpitations
- Agitation
- Anxiety
- Irritability
- Mood swings
- Elevated mood
Nonpharmacological Management of ADHD
- Behavioral therapy
- Patient and parent cognitive behavioral training program
- Psychoeducation
- Treatment of learning disorders
- Family therapy and education
Borderline personality disorder
- Impulsivity, often with self-damaging behavior
- Recurrent suicidal behavior
- Patter of unstable, intense interpersonal relationships
- Frantic efforts to avoid real or imagined abandonment
- Identity disturbances
- Chronic feelings of emptiness
- Inappropriate, intensified affective anger responses
Treatment for Borderline Personality Disorder
Nonpharmacologic Treatment: Dialectical Behavioral therapy (DBT)
Antisocial personality disorder (APD)
- Reckless disregard for welfare of others
- Lack of remorse; indifference to the feelings of others
- Failure to conform to social norms
- Repeated acts that are grounds for arrest
- Deceitfulness, lying, and use of aliases for profit or pleasure
- Impulsivity and failure of future planning
- Consistent irresponsibility
Note: - ***Both adopted and biological children of parents with APD are at increased risk for developing APD.
- ***APD is three times more commonly diagnosed in males than in females
- ***A higher frequency of APD is associated with low socioeconomic status and urban settings.
- ***APD is more common among first-degree biological relatives (both male and female) of those diagnosed with APD.
Antisocial Personality Disorder-Treatment
Nonpharmacologic Treatment:
* Cognitive Behavioral Therapy (CBT)
* Behavioral Therapy
Schizoid Personality Disorder
- Voluntary social isolation
- Indifferent to other people: Shows an apparent lack of care in relation to how others perceive them.
- Shows little to no interest in sexual activity with another person.
- Derives no pleasure in social activities
- Lacks close friends or social supports.
- Appears cold and detached
- Exhibits affective flattening
Autism spectrum disorder
Persistent deficits in social communication and social interaction across multiple settings associated with deficits in:
* Social reciprocity
* Nonverbal communication
* Developing, maintaining, and understanding relationships.
* Restricted repetitive behavior
* Stereotyped or repetitive motor movements
* Insistence on sameness
* Highly restricted with fixed interests
* **Children with autism often like to line up, stack, or organize objects and toys in long tidy rows.
Risk Factors for Autism
- Male gender
- Intellectual disability
- Genetic loading
Parents may report the following symptoms in Autism
- No response when called by name
- Little or no eye contact
- No imaginary play
- Little interest in playing with other children
- Intense tantrum
- Extremely short attention span
- Self-injurious behavior
Screening for Autism
- Modified checklist for Autism in Toddlers (M-CHAT)
- Autism Diagnostic Observation Schedule-Generic (ADOS-G)
- Ages and Stages Questionnaires (ASQ)
Pharmacological management of Autism
- Antipsychotics are effective for symptoms such as tantrums; aggressive behavior, self-injurious behavior, hyperactivity; and repetitive, stereotyped behaviors
Disruptive mood dysregulation disorder (DMDD)
- Childhood depressive disorder that is diagnosed in children older than age 6 but younger than age 18.
- Chronic dysregulated mood (“moody”)
- Frequent intense temper outbursts/tantrums
- Severe irritability
- Anger
Treatment for Disruptive mood dysregulation disorder (DMDD)
Stimulants, antipsychotics, antidepressants
Ritalin
Intermittent explosive disorder (IED)
- Involves repeated, sudden episodes of impulsive, aggressive, violent behavior, or angry verbal outbursts in which the patient reacts grossly out of proportion to the situation.
Treatment for Intermittent explosive disorder
- SSRI for example Fluoxetine
- ***Mood stabilizers: Lithium and Carbamazepine
Fragile X Syndrome
***Large head, elongated face, hyperextensible joints, abnormally large testes, short stature
Major Depressive Disorder
- Dysregulation of one or more biogenic amine neurotransmitters: Dopamine, Norepinephrine, Serotonin (DNS)
- **Cognition and memory symptoms of MDD in the older adult population (pseudodementia) often are confused with dementia-related symptoms. **
- Clients with dementia usually have a premorbid history of slowly declining cognition.
- In MDD, cognitive changes have a relatively acute onset and are significant when compared to premorbid functioning.
Pharmacological management of MDD
- Inform client that therapeutic effect may take at least 4-6 weeks
- Once started, continue antidepressants for a minimum of 6-12 months
- If the client has more than two prior episodes of MDD, consider continuing antidepressants indefinitely
- Antidepressant rebound is common when stopping antidepressants abruptly, particularly when drugs with short half-lives are involved.
- Firstline: Selective Serotonin Reuptake Inhibitors (SSRIs)
o Serious side effects are rare.
o Much safer in overdose than TCAs - **Selective serotonin reuptake inhibitors (SSRIs) serotonin and noradrenaline reuptake inhibitors (SNRIs), Bupropion, Mirtazapine, are typically used as first-line medications because their safety and tolerability may be preferable to patients and clinicians compared to those of tricyclic antidepressants (TCAs) and monoamine oxidase (MAO) inhibitors. **
- Second line: Tricyclic Antidepressants (TCAS) (refer PB page 156)
o Electrocardiogram changes and cardiac dysrhythmias are possible; avoid in clients known to have susceptibility (personal or family history). Monitor EKG before treatment and annually in older adults.
o Avoid abrupt withdrawal because of significant discontinuation syndrome.
o Avoid prescribing to people who are at high risk for suicide.
Note (refer PB page 163): All antidepressants indicated for children, adolescents, and young adults (up to age 24 years) carry a black box warning about an increase in suicidal thoughts; monitor closely for suicidal thoughts, behavior, agitation, and aggression in children taking antidepressants.
Non-Pharmacological Management of MDD
- Electroconvulsive Therapy (ECT)
- Cognitive Behavioral Therapy (CBT)
- Transcranial Magnetic Stimulation (TMS)
Electroconvulsive Therapy
- MDD with psychotic features
- Treatment resistant depression
Contraindications: - Cardiac disease
- Compromised pulmonary status
- History of brain injury or brain tumor
- Anesthesia medical complications
Adverse effects of ECT
- Possible cardiovascular effects
- Systemic effects (e.g. headaches, muscle aches, drowsiness)
- Cognitive effects (e.g. memory disturbance and confusion).
Clinical Management of Suicidality
- Always assume client is serious when he or she vocalizeds suicidal thoughts.
- Consider hospitalization
- Consider mobilizing available social resources
***Note: There is not enough evidence that the use of “no harm to self/others/safety” contracts can reduce the risk of suicide.
Bipolar Disorder
DIG FAST
* Distractibility
* Implusivity – poor judgement, spending sprees, reckless driving
* Grandiosity – increased self esteem
* Flight of ideas – racing thoughts
* Activities – psychomotor agitation
* Sleep – decreased need
* Talkativeness – pressured speech
Differences Between Bipolar I and Bipolar II
- Bipolar I and II are similar in that periods of elevated mood and symptoms of depression can occur in both types of the condition.
- The main difference between the two types is the degree to which mania presents:
-
In bipolar I disorder, a person experiences a full manic episode, which causes extreme changes in mood and energy Symptoms are severe enough that they may interfere with a person’s functioning at home, school, or work.
o During a manic episode, a person can experience symptoms for at least a week. -
In bipolar II disorder, less severe symptoms occur during a hypomanic episode.
o Symptoms of hypomania mirror those of mania, except they last for a shorter period, **at least four days, and are less severe. **
Neurotransmitter involved in mood disorder:
Dopamine, Norepinephrine, Serotonin, GABA, Glutamate.
What disorder must be ruled out when making a diagnosis of MDD?
***Bipolar Disorder
Pharmacological Management of Bipolar Disorder
- ***Lithium: Neuroprotective treatment of choice for bipolar disorder (can protect nerve cells from damage).
- Lamotrigine (Lamictal): Bipolar depression. ***
- Olanzapine in combination with Fluoxetine (Prozac) (Symbyax) is FDA approved for the treatment of bipolar depression.
- Lurasidone (Latuda) – Bipolar depression
- Divalproex sodium (Depakote) is effective in management of acute manic and depressive episodes and is also useful in prevention of relapse of both manic and depressive episodes.
- Carbamazepine can be used to treat manic episodes associated with bipolar disorder.
Nonpharmacological of Bipolar Disorder
- Cognitive behavioral therapy (CBT)
- Behavioral therapies
- Interpersonal therapies
- Supportive groups
Normal values of Free thyroxine T4 (FT4)
normal values 0.8 to 2.8 ng/dl
Thyroid disorders
- FT4 test is done to determine thyroid status, to rule out hypo- and hyperthyroidism, and to evaluate thyroid therapy
- Thyroid-stimulating hormone (0.5-5.0 Mu/L)
- TSH testing is commonly performed to establish the diagnosis of primary hypothyroidism.
- When T3 and T4 are high (hyperthyroidism), TSH secretion decreases
- When T3 and T4 are low (hypothyroidism), TSH secretion increases.
Normal TSH level
***0.5-5.0 Mu/L
Symptoms of Hypothyroidism (decreased T4, increased TSH)
- Sensitive to cold (cold intolerance)
- Confusion
- Decreased libido
- Impotence
- Decreased appetite
- Memory loss
- Lethargy
- Constipation
- Headaches
- Slow or clumsy movements
- Weight gain